Simbolo, Michele
 Distribuzione geografica
Continente #
EU - Europa 2.356
NA - Nord America 2.142
AS - Asia 1.052
SA - Sud America 10
OC - Oceania 7
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.573
Nazione #
US - Stati Uniti d'America 2.132
CN - Cina 830
GB - Regno Unito 731
IT - Italia 453
SE - Svezia 269
IE - Irlanda 233
FR - Francia 186
RU - Federazione Russa 152
DE - Germania 145
SG - Singapore 95
FI - Finlandia 81
UA - Ucraina 34
KR - Corea 28
VN - Vietnam 27
BE - Belgio 22
JP - Giappone 20
AT - Austria 14
IR - Iran 10
NL - Olanda 10
HK - Hong Kong 8
TR - Turchia 8
AU - Australia 7
CA - Canada 7
IN - India 5
LV - Lettonia 5
KG - Kirghizistan 4
BG - Bulgaria 3
BR - Brasile 3
CZ - Repubblica Ceca 3
ES - Italia 3
IL - Israele 3
MA - Marocco 3
SA - Arabia Saudita 3
AL - Albania 2
CL - Cile 2
CR - Costa Rica 2
EU - Europa 2
LK - Sri Lanka 2
NO - Norvegia 2
PH - Filippine 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
AR - Argentina 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
EC - Ecuador 1
EG - Egitto 1
FK - Isole Falkland (Malvinas) 1
ID - Indonesia 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
TW - Taiwan 1
Totale 5.573
Città #
Southend 698
Chandler 507
Dublin 229
Beijing 190
Verona 190
Ann Arbor 146
Woodbridge 143
Jacksonville 134
Ashburn 116
New York 100
Jinan 86
Redmond 78
Lawrence 72
Princeton 72
Wilmington 68
Singapore 63
Shenyang 62
Nanjing 53
Helsinki 38
Tianjin 34
Hebei 33
Zhengzhou 33
Bologna 32
Houston 31
Haikou 29
Ningbo 28
Sindelfingen 28
Nanchang 26
Seoul 24
Changsha 23
Milan 23
Brussels 22
Hangzhou 22
Taizhou 21
Kent 19
Dearborn 18
Seattle 18
Falls Church 16
Guangzhou 16
Jiaxing 16
Tokyo 16
Dallas 15
Taiyuan 15
Dong Ket 14
Redwood City 14
Vienna 14
Los Angeles 13
Norwalk 12
Fuzhou 10
Washington 10
Cagliari 8
Shanghai 8
Chions 7
Lanzhou 7
Auburn Hills 6
Boardman 6
Boydton 6
Dongguan 6
Fairfield 6
Brescia 5
Hong Kong 5
Lappeenranta 5
Munich 5
Rome 5
San Francisco 5
Zanjan 5
Bishkek 4
Bressanone 4
Chicago 4
Düsseldorf 4
Lancaster 4
Melbourne 4
Riga 4
Toronto 4
Yongin-si 4
Amsterdam 3
Arzignano 3
Bolzano 3
Menlo Park 3
Orlando 3
Osaka 3
Padova 3
Paris 3
Pieve di Soligo 3
Riva 3
Sacramento 3
San Diego 3
St Louis 3
Villafranca Di Verona 3
Bari 2
Brno 2
Castelnuovo 2
Central 2
Charlottesville 2
Clearwater 2
Colombo 2
Des Moines 2
Edinburgh 2
Esslingen am Neckar 2
Falkenstein 2
Totale 3.885
Nome #
Whole-genome landscape of pancreatic neuroendocrine tumours 161
DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples 155
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 145
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 136
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 132
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 127
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 121
Reporting tumor molecular heterogeneity in histopathological diagnosis 120
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 118
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. 114
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 113
Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients 109
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 102
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 100
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 97
Next-generation sequencing for genetic testing of familial colorectal cancer syndromes 93
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 93
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 88
A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics 87
Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing 87
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 84
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 84
Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma 83
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 81
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 81
Techniques and New Diagnostic Technologies (Limitations, Applications) 79
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 77
Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers 76
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 76
MULTIGENE MUTATIONAL PROFILING OF CHOLANGIOCARCINOMAS IDENTIFIES ACTIONABLE MOLECULAR SUBGROUPS 75
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 75
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis 74
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 73
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 73
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer 71
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations 70
Exosomal miRNA signatures of pancreatic lesions 70
New genomic landscapes and therapeutic targets for biliary tract cancers 68
FrequentNRG1fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression 67
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 67
Comparative Lesions Analysis Through a Targeted Sequencing Approach 67
Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma 63
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 61
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 61
Il profilo molecolare 60
Collapse of the Plasmacytoid Dendritic Cells compartment in advanced cutaneous melanomas by components of the tumor cell secretome 59
IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation 58
H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology 57
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 54
Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients 54
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 54
MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma 52
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 50
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 50
Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC) 49
Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology 49
Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival 48
Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis 48
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 48
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 47
Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? 46
Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors 46
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 44
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 43
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 40
Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series 40
Poorly Cohesive Gastric Cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively 40
Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumours display divergent genomic and transcriptomic profiles 38
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities 38
pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells 35
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 34
Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades 34
Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature 34
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 34
Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 32
Exploring the molecular and biological background of lung neuroendocrine tumours 31
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 29
Long-term organoid culture of a small intestinal neuroendocrine tumor 28
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 26
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 25
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 24
Atypical meningiomas with an immunohistochemical profile consistent with hypermetabolic or proliferative molecular groups show high mitotic index, chromosomal instability, and higher recurrence risk 22
An Insight on Functioning Pancreatic Neuroendocrine Neoplasms 22
An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide 19
Lung carcinoid tumours: histology and Ki-67, the eternal rivalry 16
Ascl1 and OTP tumor expressions are associated with Disease-Free Survival in Lung Atypical Carcinoids 14
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 11
Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report 10
Tubulocystic Carcinoma of Bile Ducts: A Distinct Type of Cholangiocarcinoma Associated With Adenofibroma-type Lesions 9
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms 7
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives 7
Editorial: Primary and acquired resistance in lung cancer 6
Totale 5.775
Categoria #
all - tutte 22.844
article - articoli 20.565
book - libri 0
conference - conferenze 1.107
curatela - curatele 0
other - altro 739
patent - brevetti 0
selected - selezionate 0
volume - volumi 433
Totale 45.688


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020532 0 0 45 18 62 53 78 35 41 52 83 65
2020/2021651 122 98 27 91 64 47 13 12 27 21 74 55
2021/2022824 77 227 44 70 44 18 36 51 37 17 58 145
2022/20231.484 88 172 112 256 127 351 16 84 198 17 34 29
2023/2024867 40 59 82 91 109 154 49 63 12 53 131 24
2024/2025267 115 119 33 0 0 0 0 0 0 0 0 0
Totale 5.775